QIAGEN N.V.
corporate_fare Company Profile
QIAGEN N.V. (NYSE:QGEN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 16 items for QGEN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 8/10. Across its 16 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for QGEN spans SC14D9C, 6-K, 20-F.
Recent high-impact activity:
- Qiagen Beats Q3 Outlook, Suspends 2026 Guidance Pending EQT Takeover
- QIAGEN Board Accepts EQT's €46.50/Share Takeover, Valuing Company at $12.1B
- QIAGEN Signs Definitive EQT Deal at €46.50/Share; Q3 Sales $548M, FY26 Outlook Suspended
- EQT Nears €9.6B Takeover of Qiagen at €46.50 a Share; Board Approval Could Come Wednesday
- EQT in Advanced Talks to Buy Qiagen With Binding Offer Above $50/Share
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 6,404,422 shares in QGEN as of the October 30, 2026 settlement, a 11.1% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 64.6% of QGEN volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
QGEN files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.